



201 Technology Drive • Irvine • California • 92618  
Telephone: (949) 450-5400  
Facsimile: (949) 450-5300  
Email: IR@endocare.com  
Website: [www.endocare.com](http://www.endocare.com)

FOR RELEASE on August 13, 2008 at 6:00 am (EDT)

Investor Contact:

Matt Clawson  
Allen & Caron, Inc.  
(949) 474-4300  
[matt@allencaron.com](mailto:matt@allencaron.com)  
[www.allencaron.com](http://www.allencaron.com)

Media Contact:

Len Hall  
Allen & Caron, Inc.  
(949) 474-4300  
[len@allencaron.com](mailto:len@allencaron.com)  
[www.allencaron.com](http://www.allencaron.com)

For Additional Information:

Craig T. Davenport, CEO  
Michael R. Rodriguez, CFO  
Endocare, Inc.  
(949) 450-5400  
[www.endocare.com](http://www.endocare.com)

**ENDOCARE REJECTS UNSOLICITED PROPOSAL FROM HEALTHTRONICS**

IRVINE, Calif. (August 13, 2008) . . . Endocare, Inc. (NASDAQ:ENDO) announced today that its Board of Directors has unanimously rejected the unsolicited proposal from HealthTronics, Inc. (NASDAQ: HTRN) to purchase all of the outstanding shares of Endocare for \$2.28 per share. After careful evaluation, the Board determined that the proposal is inadequate and not in the best interests of Endocare's stockholders.

**About Endocare**

Endocare, Inc.—[www.endocare.com](http://www.endocare.com)— is an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###